U.S. Connected Respiratory Care Devices Market

Market Outlook

By 2032, the U.S. Connected Respiratory Care Devices Market is projected to reach approximately USD 12.12 billion, expanding at a CAGR of 13.0% during the forecast period 2027–2032. The market was valued at USD 5.82 billion in 2026, following historical expansion from approximately USD 4.13 billion in 2023 to USD 5.13 billion in 2025. Values in this report are expressed in USD billions.

For this report, connected respiratory care devices comprise medically relevant respiratory devices in which embedded connectivity, sensors, cloud-linked management, automated data transmission, remote configuration, adherence tracking, physiological monitoring, or clinician-facing analytics form an integral part of the care pathway. The scope includes connected positive airway pressure systems, non-invasive and invasive ventilatory support devices, connected oxygen therapy platforms, smart inhalers and nebulizers, connected spirometry and diagnostic devices, pulse oximetry and respiratory monitoring systems, and associated device-management platforms. Standalone telehealth software, general-purpose consumer wearables, pharmaceutical revenue, and non-connected conventional respiratory equipment are excluded.

The U.S. respiratory care market is moving from equipment-centered treatment toward continuous, data-enabled management of chronic respiratory disease. Historically, respiratory device purchasing focused on airflow generation, oxygen delivery, medication delivery, ventilation accuracy, or diagnostic measurement. The connected-care model adds another layer of value: whether clinicians, durable medical equipment providers, sleep laboratories, health systems, and patients can determine if therapy is being used, whether treatment is effective, whether deterioration is occurring, and where intervention should be prioritized.

This transition is commercially significant because respiratory disease management is particularly suitable for remote care. Obstructive sleep apnea requires nightly therapy and adherence monitoring. COPD involves recurrent exacerbation risk and expensive acute-care utilization. Asthma outcomes depend heavily on medication technique and adherence. Patients on home oxygen or non-invasive ventilation may require long-duration therapy and equipment servicing. These characteristics create a large addressable base for connected devices that turn therapy usage and physiological signals into actionable clinical information.

The market has therefore developed beyond a traditional replacement-cycle model. A connected PAP machine, oxygen concentrator, ventilator, inhaler sensor, or spirometer increasingly participates in a larger ecosystem involving patient onboarding, device setup, adherence management, clinical dashboards, automated alerts, remote therapeutic monitoring, reimbursement documentation, equipment servicing, and outcomes measurement. Manufacturers able to integrate these functions are positioned to capture a larger share of the economic value surrounding each respiratory patient.

Historical growth from 2023 through 2025 was supported by home-based care adoption, normalization of connected sleep therapy, expansion of remote monitoring infrastructure, respiratory staffing constraints, growing demand for outpatient disease management, and wider acceptance of cloud-managed durable medical equipment. The 2027–2032 forecast period is expected to accelerate this transformation as connectivity becomes standard across premium respiratory platforms rather than an optional device feature.

Introduction

According to the U.S. Connected Respiratory Care Devices Market assessment, the commercial opportunity sits at the intersection of respiratory medical devices, home healthcare, sleep medicine, pulmonary disease management, digital health infrastructure, and Medicare-supported remote care.

The underlying clinical population is substantial. More than 27 million Americans have current asthma based on recent national surveillance, while adult asthma alone affects close to one in eleven U.S. adults. COPD affects millions of adults and remains one of the country’s major chronic respiratory causes of morbidity and mortality. Nearly 30 million U.S. adults are believed to have obstructive sleep apnea, with a large majority historically remaining undiagnosed. Together, these conditions create one of the largest chronic respiratory populations in a developed healthcare market.

Respiratory care also generates persistent healthcare utilization. COPD contributes substantial emergency department, hospitalization, physician, medication, home oxygen, and post-acute expenditure. Asthma continues to generate more than one million emergency department visits in a typical year. Sleep apnea creates a large treatment population for PAP systems and increasingly home-based diagnostic technologies. Chronic respiratory failure, neuromuscular disease, obesity hypoventilation, and advanced pulmonary disease support demand for home ventilation and oxygen equipment.

Connected devices address several structural problems in these care pathways. Traditional respiratory care can provide clinicians with only episodic visibility. A physician may prescribe CPAP, oxygen, inhaled medication, or non-invasive ventilation but receive limited information between visits. Connected systems can report therapy hours, pressure, leak, respiratory rate, oxygen saturation, inhaler actuation, peak flow, spirometry, equipment alarms, or other relevant information remotely. This enables intervention to shift from scheduled review toward exception-based management.

The economics are becoming equally important. U.S. hospitals operate within an infrastructure of more than 6,000 hospitals, more than 900,000 staffed beds, and tens of millions of annual admissions. Respiratory therapists, pulmonologists, sleep specialists, nurses, DME providers, and care managers operate under persistent labor constraints. Connected respiratory systems can reduce the number of manual touchpoints needed to manage large patient populations by directing staff toward patients who require intervention.

Home healthcare economics are another major growth catalyst. Sleep therapy and home oxygen have long been centered outside the hospital, but connectivity is changing how these services are managed. DME and HME providers increasingly value devices that simplify onboarding, document utilization, identify mask or equipment problems, support compliance requirements, automate resupply workflows, and reduce avoidable service calls.

The U.S. reimbursement framework also supports the transition. Medicare remote physiologic monitoring pathways permit the use of connected medical devices that automatically transmit physiological information. Respiratory-specific remote therapeutic monitoring pathways support monitoring of therapy adherence and response. From 2026, respiratory RTM coding accommodates both shorter 2–15-day monitoring periods and longer 16–30-day periods, improving the commercial flexibility of connected respiratory programs.

The result is a market where competitive advantage increasingly depends on the combination of device performance, connectivity reliability, clinical utility, workflow integration, reimbursement compatibility, cybersecurity, patient experience, and installed-base economics.

Key Market Drivers: What Is Fueling the U.S. Connected Respiratory Care Devices Market?

The first major driver is the scale of chronic respiratory disease in the United States. Current asthma affects more than 27 million Americans, while recent national data place adult asthma prevalence above 8%. COPD prevalence increases sharply with age and remains materially higher among older and nonmetropolitan populations. These disease pools support recurring demand for connected inhalation, spirometry, oxygen therapy, non-invasive ventilation, pulse oximetry, and disease-monitoring technologies.

The second driver is the size of the obstructive sleep apnea population. Nearly 30 million American adults are affected by OSA, yet historically only a fraction have been diagnosed and treated. This creates a substantial long-term opportunity for home sleep testing, cloud-connected PAP systems, patient engagement applications, adherence analytics, remote troubleshooting, and automated therapy optimization. Because PAP treatment generates nightly usage data, sleep therapy is one of the most digitally mature segments of respiratory care.

The third driver is migration from hospital-centric treatment toward the home. Connected respiratory devices allow clinically appropriate patients to be treated, monitored, or supported outside expensive acute-care environments. Home oxygen concentrators, PAP systems, non-invasive ventilators, smart nebulizers, and portable respiratory diagnostics can reduce the need for repeated facility-based interaction when combined with appropriate clinical oversight.

The fourth driver is reimbursement support for remote care. The establishment and continued refinement of RPM and RTM coding has given U.S. providers a clearer economic pathway for certain remote monitoring activities. Respiratory-specific RTM is particularly relevant because it can capture therapy adherence and therapeutic response rather than only physiological measurements. This makes connected respiratory technology commercially relevant not only to manufacturers but also to physician practices, pulmonary groups, allergists, health systems, and care-management organizations.

A fifth driver is workforce economics. Respiratory therapy departments, sleep laboratories, DME companies, nursing teams, and specialty practices cannot scale labor linearly with patient growth. Connected platforms can enable one clinician or care-management team to manage substantially larger patient populations by stratifying patients according to therapy use, alarms, deteriorating metrics, or intervention needs. For buyers, the question is increasingly whether the technology reduces labor intensity per managed patient.

A sixth driver is hospital pressure to reduce readmissions and avoidable acute utilization. COPD exacerbations, respiratory failure, pneumonia-related deterioration, and oxygen-dependent disease can produce expensive emergency and inpatient episodes. Connected monitoring does not eliminate these events, but well-designed systems can improve visibility into patient status and therapy adherence before deterioration reaches crisis level.

A seventh driver is the growing importance of patient adherence. Respiratory outcomes often depend on whether the prescribed device is actually used. PAP adherence, inhaler adherence, oxygen utilization, and non-invasive ventilation hours are therefore commercially meaningful data. Connected devices convert adherence from a self-reported behavior into measurable information that can be used by clinicians, payers, DME providers, and patients.

Finally, the connected respiratory market benefits from a strong U.S. medical technology ecosystem. Large medtech companies, respiratory specialists, digital respiratory innovators, cloud-platform developers, and remote monitoring companies are competing for control of longitudinal respiratory workflows. Innovation is therefore occurring across hardware, sensors, embedded software, cloud architecture, artificial intelligence, patient engagement, and clinical decision support simultaneously.

Innovation in Focus: How Manufacturers Are Raising the Bar

The strongest innovation trend is the shift from connected hardware to intelligent respiratory ecosystems. Connectivity alone has become insufficient differentiation in mature segments such as PAP therapy. The competitive frontier is moving toward platforms that interpret device data, identify clinically meaningful exceptions, recommend interventions, automate patient communication, and integrate information across the care network.

Sleep therapy illustrates this progression. Cloud-connected PAP systems can already report usage, pressure, leakage, residual respiratory events, and adherence. The next phase involves machine learning and AI-assisted personalization, proactive patient coaching, remote troubleshooting, and increasingly automated comfort or therapy-setting recommendations. Leading respiratory platforms now operate across tens of millions of cloud-connected patient relationships, demonstrating that connected respiratory care has already achieved substantial real-world scale.

Connected ventilation is evolving in parallel. Home ventilators and non-invasive ventilation systems increasingly support remote visibility into usage and device performance. For providers managing patients with chronic respiratory failure, neuromuscular disease, severe COPD, or hypoventilation syndromes, connectivity can improve equipment management and help care teams identify deviations from prescribed therapy. Integration with oxygen saturation, respiratory rate, or other physiological parameters can further strengthen clinical relevance.

Connected oxygen therapy represents another important innovation area. Portable oxygen concentrators have already improved mobility compared with traditional cylinder-dependent models. The addition of device telemetry can support utilization tracking, equipment diagnostics, battery management, service planning, and fleet optimization for DME providers. Future systems are likely to combine oxygen-device information with patient physiological data, allowing care models to move from equipment supply toward longitudinal oxygen-management services.

Smart inhalation is also developing from simple actuation counting toward clinically useful treatment intelligence. Connected inhalers and add-on sensors can record when medication is taken, identify missed doses, track rescue inhaler utilization, and potentially associate medication use with symptoms or environmental conditions. For asthma and COPD, the highest value will come from systems capable of distinguishing poor adherence from poor treatment response.

Connected respiratory diagnostics are becoming more distributed. Portable spirometers, home sleep tests, pulse oximeters, wearable respiratory sensors, and other compact monitoring technologies are moving measurements previously confined to clinics into the home. The economic value comes not simply from collecting data remotely but from generating information that is reliable enough to support clinical decisions without creating excessive review burden.

Cybersecurity has simultaneously become a product requirement. Internet-connected medical devices are now evaluated within a regulatory environment that expects cybersecurity risk management, vulnerability planning, software-component transparency, and lifecycle controls. For respiratory manufacturers, cybersecurity is increasingly a procurement issue as well as a regulatory issue because connected devices may sit on hospital networks, transmit protected health information, receive remote updates, and remain in service for years.

Segmentation Insights

The U.S. Connected Respiratory Care Devices Market is segmented on the basis of product category, disease indication, primary connectivity architecture, end user, distribution and commercial channel, and region.

By Product Category

Connected PAP and sleep therapy systems represented the largest product category in 2026, accounting for approximately 34% of market revenue, or USD 1.98 billion. This category includes connected CPAP, APAP and bilevel systems, cloud-based therapy management, home sleep diagnostic devices, adherence platforms, and compatible accessories where digital management forms part of the value proposition. The segment benefits from a large OSA patient pool and the maturity of remote PAP compliance management. Sleep therapy is expected to remain the largest connected respiratory category through 2032, although its share may moderate as oxygen, inhalation, and respiratory monitoring platforms digitize more rapidly.
Connected ventilators and non-invasive ventilation systems accounted for approximately 19%, equivalent to USD 1.11 billion in 2026. The segment includes cloud-capable home ventilators, bilevel respiratory support platforms, non-invasive ventilation devices, life-support ventilation systems with remote connectivity modules, and associated management software. Growth is supported by aging patients, chronic respiratory failure, neuromuscular conditions, severe COPD, and increasing emphasis on managing clinically appropriate ventilated patients outside acute-care environments.
Connected oxygen therapy devices generated approximately 18% of the market, or USD 1.05 billion in 2026. Portable and stationary oxygen concentrators, telemetry-enabled oxygen equipment, remote equipment management platforms, and oxygen-linked patient monitoring form the core of this category. The U.S. opportunity is strengthened by the scale of Medicare home oxygen utilization and the operational benefits of remotely managing equipment fleets. This segment should grow above the conventional oxygen equipment market as DME suppliers place greater emphasis on connected serviceability and patient visibility.
Smart inhalers and connected nebulizers represented approximately 15%, or USD 0.87 billion in 2026. This includes integrated digital inhalers, add-on medication sensors, connected nebulizer systems, adherence applications, and clinician-facing therapeutic monitoring tools. The commercial opportunity is concentrated in asthma and COPD because medication non-adherence, incorrect technique, overuse of rescue medication, and poor visibility between clinic visits remain persistent problems. Respiratory-specific RTM reimbursement strengthens the strategic relevance of this category.
Connected respiratory monitoring and diagnostic devices accounted for approximately 14%, equivalent to USD 0.81 billion in 2026. Products include connected spirometers, peak-flow meters, pulse oximeters, respiratory-rate sensors, wearable respiratory monitors, home sleep testing technologies, capnography-linked systems, and multi-parameter monitoring devices. This is expected to be one of the faster-growing categories as respiratory care increasingly depends on home-generated objective data.

By Disease Indication

Obstructive sleep apnea was the largest disease-indication segment, representing approximately 32% of the 2026 market, or USD 1.86 billion. Nearly 30 million U.S. adults are affected by OSA, while historically around four in five cases have remained undiagnosed. The combination of a large underdiagnosed population, home-based diagnostic expansion, nightly PAP data generation, and strong manufacturer investment makes OSA the most mature connected respiratory workflow.
COPD accounted for approximately 28%, or USD 1.63 billion in 2026. Recent national data place diagnosed COPD prevalence at roughly 4% of U.S. adults, with prevalence rising substantially among older populations. COPD also produces significant emergency and inpatient utilization, creating strong health-system interest in exacerbation prediction, inhaler adherence, oxygen monitoring, home ventilation, pulse oximetry, and post-discharge management. COPD is expected to remain one of the strongest long-term opportunities for connected respiratory manufacturers.
Asthma represented approximately 17%, equivalent to USD 0.99 billion in 2026. More than 27 million Americans have current asthma, including millions of children. Connected inhalers, nebulizers, peak-flow meters, spirometry, symptom tracking, and therapeutic monitoring platforms are especially relevant for patients with poor medication adherence or recurrent exacerbations. States with higher asthma prevalence create additional opportunities for payer- and health-system-sponsored digital disease-management programs.
Chronic respiratory failure and home ventilation indications accounted for approximately 13%, or USD 0.76 billion in 2026. This includes severe COPD, neuromuscular disorders, obesity hypoventilation, restrictive thoracic disorders, and other conditions requiring long-duration ventilatory support. The segment has lower patient volume than asthma or OSA but significantly higher device value per patient and greater clinical complexity.
Post-acute respiratory management and other respiratory indications generated approximately 10%, or USD 0.58 billion in 2026. This includes recovery after respiratory hospitalization, pneumonia-related monitoring, selected pulmonary rehabilitation pathways, bronchiectasis, cystic fibrosis-related monitoring, interstitial lung disease, and other conditions where remote respiratory data may support longitudinal care.

By Primary Connectivity Architecture

Cellular-connected systems represented approximately 32% of 2026 revenue, or USD 1.86 billion. Cellular connectivity is highly valuable in respiratory care because it can transmit device information without depending on the patient’s home Wi-Fi configuration. It is particularly relevant to PAP, ventilation, and DME-managed equipment where low-friction deployment matters.
Bluetooth and smartphone-connected devices accounted for approximately 27%, or USD 1.57 billion in 2026. This architecture is prominent in smart inhalers, portable diagnostics, pulse oximetry, spirometry, and patient-facing applications. Smartphone connectivity lowers embedded communication costs and improves patient engagement, although performance depends on pairing, application use, and patient digital literacy.
Wi-Fi and direct cloud-connected systems represented approximately 21%, equivalent to USD 1.22 billion in 2026. Wi-Fi is common where large data transfers, software updates, or home monitoring ecosystems are required. Adoption is strongest among digitally engaged patient populations and integrated home-health environments.
Gateway-based and multi-parameter connectivity architectures accounted for approximately 12%, or USD 0.70 billion in 2026. These solutions aggregate information from multiple devices before sending data to the clinical platform. They are strategically important for complex respiratory patients requiring combinations of ventilation, oxygen saturation, oxygen therapy, activity, weight, or other physiological measurements.
AI-enabled and advanced analytics-centric connected architectures represented approximately 8%, or USD 0.47 billion in 2026, when classified by the primary commercial differentiation of the platform. Although smaller today, this is expected to be the fastest-growing technology layer. AI will increasingly support adherence risk prediction, patient prioritization, therapy personalization, signal interpretation, and workload reduction.

By End User

Home healthcare and DME/HME providers were the largest end-user group, accounting for approximately 38% of 2026 revenue, or USD 2.21 billion. These organizations are central to PAP, home oxygen, ventilation, and related equipment workflows. Connected equipment can lower servicing costs, automate compliance documentation, improve resupply management, reduce unnecessary patient calls, and increase the number of patients a care team can manage.
Hospitals and integrated health systems represented approximately 29%, or USD 1.69 billion in 2026. Hospitals purchase connected ventilators, respiratory monitoring systems, pulse oximetry, capnography, transitional-care technologies, and devices that support discharge into home-based care. Large IDNs increasingly assess connected respiratory platforms through enterprise interoperability, cybersecurity, clinical outcomes, and total-cost-of-care criteria rather than device acquisition price alone.
Sleep centers, pulmonary practices, allergy practices, and specialty physician groups accounted for approximately 15%, equivalent to USD 0.87 billion in 2026. These users benefit from remote access to PAP, spirometry, inhaler, and other respiratory data. Connected systems also allow specialty practices to extend clinical visibility beyond episodic office appointments.
Ambulatory, urgent-care, and other outpatient settings represented approximately 10%, or USD 0.58 billion in 2026. Compact connected diagnostics, spirometry, pulse oximetry, nebulization, and remote follow-up solutions are increasingly relevant as respiratory care migrates away from hospital campuses.
Skilled nursing, long-term care, and post-acute providers represented approximately 8%, or USD 0.47 billion in 2026. These organizations manage older patients with high COPD, sleep-disordered breathing, oxygen, and respiratory-support requirements. Connected technology can assist with monitoring while reducing dependence on specialist availability onsite.

By Distribution and Commercial Channel

DME and HME provider networks accounted for approximately 36% of market value, or USD 2.10 billion in 2026. They remain the primary route for PAP, home oxygen, ventilation, and related respiratory equipment. Manufacturers that reduce device setup, service calls, compliance management costs, and inventory complexity are well positioned within this channel.
Direct manufacturer-to-hospital and IDN contracting represented approximately 27%, or USD 1.57 billion in 2026. Large health systems increasingly favor enterprise agreements combining equipment, software, service, training, cybersecurity support, and analytics.
Retail and specialty pharmacy channels represented approximately 15%, equivalent to USD 0.87 billion in 2026, driven primarily by inhalation devices, medication-linked sensors, nebulization products, and selected monitoring equipment.
Online and direct-to-consumer channels accounted for approximately 12%, or USD 0.70 billion in 2026. Home sleep diagnostics, portable oximetry, spirometry, certain PAP-related technologies, and portable oxygen products increasingly use digitally enabled customer acquisition, although prescription and coverage requirements continue to shape the addressable market.
Payer-sponsored, value-based, and managed-care channels represented approximately 10%, or USD 0.58 billion in 2026. This channel is strategically important because connected respiratory care can be contracted around utilization reduction, therapy adherence, risk stratification, and disease-management outcomes rather than device sales alone.

Regional Insights: Where the Market Is Growing Fastest

The U.S. Connected Respiratory Care Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs according to population scale, respiratory disease prevalence, age distribution, rurality, Medicare concentration, health-system consolidation, specialist density, air quality exposure, DME infrastructure, technology adoption, and payer sophistication.

The South is the largest regional market, while the West is expected to record the fastest growth through 2032. The Northeast remains a high-value market for connected specialty respiratory care and academically driven adoption, while the Midwest provides a large base of sleep, COPD, oxygen, and home-care demand.

South

The South accounted for approximately USD 2.10 billion in 2026, representing about 36% of the national market. The regional market is projected to approach USD 4.42 billion by 2032, implying growth of roughly 13.2% annually.

Texas and Florida are the two largest state opportunities in the region. Texas combines a population exceeding 30 million with major healthcare markets in Houston, Dallas–Fort Worth, Austin, and San Antonio. Its scale supports connected sleep therapy, asthma management, COPD monitoring, oxygen therapy, ventilation, and hospital respiratory systems. Florida is particularly attractive for connected oxygen, PAP, COPD, and post-acute respiratory care because of its large older population and extensive Medicare-oriented healthcare infrastructure.

North Carolina, Georgia, Virginia, and Tennessee represent high-growth secondary markets. North Carolina combines rapid population growth with major academic and integrated healthcare networks. Georgia’s large Atlanta-centered healthcare ecosystem and substantial asthma burden support connected inhalation and pulmonary care. Virginia combines advanced health systems with large suburban populations, while Tennessee has a significant chronic respiratory burden and expanding health-system footprint.

Maryland and Delaware benefit from dense healthcare networks and proximity to major Northeast provider systems. The District of Columbia has a smaller absolute market but above-average chronic respiratory management intensity and access to large academic systems.

Kentucky, West Virginia, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, and South Carolina are particularly important from a disease-burden perspective. West Virginia has one of the highest adult asthma prevalence rates in the country and historically high COPD prevalence. Kentucky, Tennessee, Alabama, and surrounding states have substantial smoking-associated respiratory disease and rural access challenges. These characteristics strengthen the value proposition for home oxygen, non-invasive ventilation, connected PAP, tele-pulmonology support, and remote therapeutic monitoring.

State-level market opportunities across the South can therefore be divided between high-volume metropolitan markets and high-need rural markets. Texas, Florida, Georgia, North Carolina, Virginia, Maryland, Tennessee, South Carolina, Alabama, Mississippi, Louisiana, Kentucky, West Virginia, Arkansas, Oklahoma, Delaware, and the District of Columbia all represent differentiated commercial territories rather than a single homogeneous respiratory market.

West

The West accounted for approximately USD 1.40 billion in 2026, or about 24% of the U.S. market, and is expected to reach approximately USD 3.26 billion by 2032. Its implied CAGR of approximately 15.1% makes it the fastest-growing regional market.

California is the largest Western state opportunity. Its scale, concentration of technology-oriented health systems, sophisticated managed-care environment, large asthma population, and significant digital-health ecosystem make it an early-adoption market for connected respiratory diagnostics, remote patient monitoring, smart inhalation, PAP platforms, AI-enabled clinical workflows, and hospital-to-home respiratory care.

Washington and Oregon are also strong connected-care markets because major integrated health systems have long experience with population health, telehealth, and coordinated chronic disease management. Adult asthma prevalence in both states is comparatively high, further increasing the relevance of connected respiratory management.

Arizona and Nevada combine rapid population growth with increasing older-adult populations. These states are attractive for sleep therapy, home oxygen, COPD management, and portable respiratory equipment. Arizona’s large retiree population in particular supports home respiratory demand.

Colorado and Utah benefit from growing populations, strong digital-health adoption, sophisticated delivery networks, and established respiratory specialty care. Colorado also reports adult asthma prevalence above the national level, supporting connected inhalation and monitoring technologies.

New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii have smaller absolute device markets but compelling remote-care economics. Geography and specialist access can make digital connectivity disproportionately valuable in these states. Alaska, Montana, Wyoming, and parts of Idaho and New Mexico have large rural service areas where remote respiratory monitoring can reduce travel requirements and improve continuity between specialist visits. Hawaii’s island geography similarly increases the relevance of digitally coordinated home respiratory care.

The full Western opportunity therefore includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii, with California dominating absolute revenue but Mountain West states contributing faster percentage growth.

Northeast

The Northeast generated approximately USD 1.34 billion in 2026, representing roughly 23% of the national market, and is projected to reach approximately USD 2.57 billion by 2032, corresponding to growth of around 11.5% annually.

The Northeast is particularly important for high-acuity pulmonary medicine, sleep medicine, clinical research, advanced hospital respiratory monitoring, and early evaluation of connected-care technology. Large academic health systems are concentrated throughout Boston, New York City, Philadelphia, Pittsburgh, northern New Jersey, Connecticut, and other major metropolitan markets.

New York is the region’s largest state opportunity because of population scale, extensive hospital infrastructure, major academic medical centers, large DME networks, and substantial asthma and sleep-disorder populations. Massachusetts has a smaller population but outsized influence on medical technology adoption because of its academic, biotechnology, digital-health, and health-system ecosystems. Adult asthma prevalence in Massachusetts is also materially above the national level.

Pennsylvania is commercially important for both urban and rural respiratory care. Philadelphia and Pittsburgh support advanced pulmonary medicine, while rural and former industrial communities contribute significant COPD and home oxygen demand. New Jersey combines high population density with close integration into major New York and Philadelphia provider markets.

Connecticut, Rhode Island, Maine, Vermont, and New Hampshire represent smaller markets by population but report comparatively high adult asthma prevalence in several cases. Maine has recently reported adult current asthma prevalence approaching 13%, while Rhode Island, Massachusetts, New Hampshire, and Vermont also rank above many large states. These epidemiological patterns make connected inhalation, home spirometry, PAP, and respiratory monitoring particularly relevant.

The Northeast therefore combines New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Maine, New Hampshire, and Vermont into a region characterized by premium technology adoption, rigorous evidence requirements, mature payer structures, and strong specialist influence.

Midwest

The Midwest accounted for approximately USD 0.98 billion in 2026, representing about 17% of the U.S. market, and is forecast to reach approximately USD 1.87 billion by 2032, equivalent to an approximate 11.4% CAGR.

Illinois, Ohio, Michigan, and Minnesota are the largest state markets. Illinois benefits from Chicago’s academic and integrated delivery networks. Ohio has substantial respiratory disease burden, large health systems, and adult asthma prevalence around the low-double-digit level. Michigan combines chronic pulmonary disease demand with a large established healthcare infrastructure. Minnesota is strategically important because of its mature medtech ecosystem and sophisticated healthcare delivery organizations.

Indiana is another important connected respiratory opportunity, with adult asthma prevalence exceeding 11% in recent state surveillance. Wisconsin, Missouri, Iowa, and Kansas provide durable demand across sleep therapy, COPD, oxygen, and respiratory monitoring.

Nebraska, North Dakota, and South Dakota are smaller markets but have a stronger need for scalable remote care because of lower population density and long travel distances between patients and specialists. Connected PAP, portable oxygen, remote spirometry, and cloud-linked monitoring are particularly relevant where conventional high-frequency specialist follow-up is operationally difficult.

The Midwest encompasses Illinois, Indiana, Ohio, Michigan, Wisconsin, Minnesota, Iowa, Missouri, Kansas, Nebraska, North Dakota, and South Dakota. Growth is expected to remain below the West and South in percentage terms, but its large chronic respiratory population and established DME infrastructure make the region commercially dependable.

Key Market Players

The U.S. Connected Respiratory Care Devices Competitive Landscape combines large respiratory-device manufacturers, hospital technology companies, home respiratory specialists, oxygen therapy providers, digital respiratory innovators, and monitoring companies. Competitive advantage is shifting from ownership of a single high-performing device toward control of the patient-management ecosystem around that device.

The most relevant companies operating across the U.S. connected respiratory care ecosystem include:

ResMed
Philips Respironics
Fisher & Paykel Healthcare
Medtronic
GE HealthCare
Masimo
Hamilton Medical
Dräger
Inogen
React Health
Drive DeVilbiss Healthcare
O2 Concepts
Breas Medical
NuvoAir
Adherium

ResMed holds one of the strongest positions in connected sleep and respiratory therapy because of the scale of its PAP installed base and cloud-connected AirView and myAir ecosystems. By fiscal 2026, its cloud-connected patient footprint had expanded beyond 35 million patients, with more than 12 million patients registered on myAir. This scale creates a substantial data, workflow, and customer-retention advantage.

Philips Respironics retains a historically important installed base across sleep and respiratory care, although its U.S. competitive position has been materially affected by the major CPAP, BiPAP, and ventilator recall and the 2024 U.S. consent decree restricting production and sale of certain new devices until specified requirements are satisfied. This disruption has influenced purchasing behavior and allowed competitors to capture additional connected PAP and respiratory demand.

Fisher & Paykel Healthcare is strategically relevant through respiratory humidification, hospital respiratory care, and sleep apnea interfaces and systems. Hamilton Medical and Dräger are important in connected ventilation and critical-care respiratory ecosystems, while Medtronic retains relevance across ventilation and monitoring technologies.

Inogen, O2 Concepts, Drive DeVilbiss, and React Health compete more directly across home oxygen, PAP, ventilation, and durable respiratory equipment. Their future competitiveness will depend increasingly on telemetry, serviceability, patient applications, fleet management, and integration into DME workflows.

NuvoAir and Adherium represent the more digitally focused side of the market, with connected spirometry, therapeutic monitoring, adherence, and remote respiratory management capabilities. These firms illustrate how competitive differentiation is moving beyond hardware manufacturing toward disease-specific data and care-management infrastructure.

Recent Developments

The U.S. connected respiratory market entered a new phase between 2024 and 2026 as device connectivity shifted from differentiation toward infrastructure.

One of the most important developments has been the continued expansion of large-scale connected PAP ecosystems. Leading respiratory platforms now manage tens of millions of cloud-connected patients. ResMed reported more than 35 million patients using cloud-connected devices through AirView by fiscal 2026, alongside more than 12 million myAir registrations. The company also expanded AI-enabled personalization, including an FDA-cleared feature designed to recommend personalized comfort settings for selected PAP users.

A second major development is the continued restructuring of the U.S. sleep therapy competitive environment following the Philips Respironics recall. The recall affected approximately 15 million devices globally and led to a U.S. federal consent decree in April 2024. Restrictions on production and sale of certain new Philips CPAP, BiPAP, and respiratory devices changed channel purchasing patterns and strengthened opportunities for competing PAP and home respiratory manufacturers.

A third development is the strengthening of reimbursement architecture for respiratory remote therapeutic monitoring. Beginning in 2026, the CPT structure distinguishes respiratory RTM device supply for shorter 2–15-day monitoring periods from monitoring across 16–30 days. This expands the range of potential clinical programs that can align with reimbursable remote respiratory management.

A fourth development is tightening regulatory focus on connected-device cybersecurity. Connected respiratory manufacturers must now plan cybersecurity across the entire device lifecycle, including vulnerability management, software components, updates, documentation, and post-market risk. This raises development requirements but also creates a competitive advantage for manufacturers with mature software quality and cybersecurity capabilities.

A fifth development is growing adoption of multi-parameter monitoring rather than isolated respiratory measurements. Providers increasingly want respiratory rate, oxygen saturation, therapy adherence, activity, sleep, symptoms, and other data synthesized into a manageable clinical workflow. The commercial opportunity is therefore moving from sensors that generate data toward platforms that reduce the amount of data clinicians must manually review.

The next competitive cycle will likely focus on automated triage, predictive exacerbation analytics, connected oxygen management, AI-guided PAP therapy, home spirometry, digitally managed ventilation, smart medication delivery, and tighter integration between device platforms and health-system clinical information systems.

Conclusion

The U.S. Connected Respiratory Care Devices Market Size & Share is positioned to expand from USD 5.82 billion in 2026 to approximately USD 12.12 billion by 2032, representing a 13.0% CAGR during 2027–2032.

The market’s long-term growth is supported by a convergence of clinical need and healthcare economics. Asthma, COPD, obstructive sleep apnea, chronic respiratory failure, and oxygen-dependent disease create a large addressable patient population. At the same time, U.S. providers face pressure to manage more patients with limited specialist and respiratory-care staffing, reduce avoidable acute utilization, move appropriate care into the home, and document therapy adherence more effectively.

Connected PAP and sleep therapy currently provide the largest revenue base, reflecting the maturity of cloud-enabled sleep management. However, some of the strongest incremental opportunities through 2032 will emerge from connected oxygen therapy, digitally managed ventilation, respiratory RTM, smart inhalation, home spirometry, multi-parameter respiratory monitoring, and AI-enabled patient prioritization.

The commercial model is also changing. Device manufacturers can no longer evaluate opportunity purely in units sold and average selling price. Increasingly, value is created across the entire patient lifecycle: diagnosis, device initiation, onboarding, adherence, remote monitoring, troubleshooting, resupply, intervention, outcomes documentation, and replacement.

For hospitals and IDNs, the winning technologies will be those that demonstrate interoperability, cybersecurity, workflow efficiency, reduction in manual monitoring burden, and potential impact on utilization. For DME providers, success will depend on lower servicing cost, stronger compliance management, better fleet visibility, automated patient support, and scalable resupply. For physician practices, remote therapeutic and physiologic monitoring economics will make the quality and usability of connected data increasingly important.

Geographically, the South will remain the largest market, supported by Texas, Florida, Georgia, North Carolina, Virginia, Tennessee, and high respiratory disease burden across several Southeastern states. The West will deliver the fastest growth, led by California and digitally advanced health systems across Washington, Oregon, Colorado, Utah, Arizona, and other growth markets. The Northeast will remain a premium, evidence-intensive connected-care market, while the Midwest will continue to provide stable respiratory device demand and significant opportunities for remote care across rural populations.

For companies assessing this market, the strategic question is no longer whether respiratory devices will become connected. Connectivity is becoming a baseline requirement across premium respiratory care. The more consequential question is which companies can convert connectivity into measurable clinical and economic value.

Manufacturers that combine reliable respiratory hardware with longitudinal patient data, secure cloud infrastructure, actionable analytics, reimbursement-compatible workflows, strong DME integration, clinical evidence, and scalable patient engagement will be best positioned to capture the next phase of U.S. respiratory device growth.